CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.600
-0.040 (-1.52%)
At close: Aug 28, 2026, 4:00 PM EDT
2.560
-0.040 (-1.54%)
After-hours: Aug 28, 2026, 7:30 PM EDT
CervoMed Employees
CervoMed had 15 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$22,086
Profits / Employee
-$2,023,316
Market Cap
39.31M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 0 | - |
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Mar 31, 2023 | 4 | - | - |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Aligos Therapeutics | 82 |
| Mereo BioPharma Group | 39 |
| Filana Therapeutics | 20 |
| Tevogen | 18 |
| BriaCell Therapeutics | 16 |
| Context Therapeutics | 15 |
| Actuate Therapeutics | 12 |
CRVO News
- 9 days ago - CervoMed price target lowered to $7 from $9 at Roth Capital - TheFly
- 18 days ago - CervoMed Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 19 days ago - CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 19 days ago - CervoMed price target lowered to $18 from $27 at Canaccord - TheFly
- 22 days ago - CervoMed Quarterly report: Q2 2026 - Filings
- 22 days ago - CervoMed Earnings release: Q2 2026 - Filings
- 24 days ago - CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - GlobeNewsWire
- 25 days ago - CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) - GlobeNewsWire